USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Mapp Biopharmaceutical, Inc.
Address:
6160 Lusk Blvd., Suite C105
San Diego, CA 92121-2740
Phone:
N/A
URL:
EIN:
200037593
DUNS:
137551797
Number of Employees:
9
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,409,744.00 8
SBIR Phase II $8,804,175.00 3
STTR Phase I $570,972.00 1

Award List:

ANTI-C. DIFFICILE HUMAN MONOCLONALS FOR IMMUNOTHERAPY

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Clostridium difficile associated disease (CDAD) is an important cause of morbidity in hospital and nursing home patients, and is being increasingly recognized as an important cause of mortality. The objective of this project is to produce human monoclonal… More

MONOCLONAL ANTIBODIES FOR ALZHEIMER'S IMMUNOTHERAPY

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$445,868.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (PROVIDED BY APPLICANT): Transgenic mice administered anti-amyloid peptide antibodies, acutely or subchronically, show markedly improved learning and memory performance. Recent reports suggest that the toxicity of the amyloid peptide and other amyloidogenic proteins lies not in the… More

Development of a C. difficile Monoclonal-based Product

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$2,988,995.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): According to the CDC, each year more than two million U.S. hospital patients contract nosocomial infections, and some 80,000 of them die as a result (Federal Register, 2004). With drug-resistant infections reaching epid emic levels-especially in medical… More

A Monoclonal Antibody Immunoprotectant for Ebola Virus

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$539,244.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The primary focus of this proposal is development of a product for protection against Ebola virus (Category A agent). Through collaboration between Mapp Biopharmaceutical and Dr. Mary Kate Hart (USAMRIID), three murine monoclonal antibodies (Mabs) that were… More

Monoclonal Antibody SEB Immunoprotectant

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$599,821.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Staphylococcal enterotoxin B (SEB; Category B agent), a toxin that commonly causes classic food poisoning and can cause a nonmenstrual toxic shock syndrome (TSS), is a potential biological warfare agent. Importantly, SE B is derived from common readily accessible… More

Monoclonal Antibodies for Alzheimer's Immunotherapy

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$2,815,180.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The primary focus of this Phase II proposal is development of a product against Alzheimer's disease (AD). AD is an increasingly important cause of morbidity and mortality in both hospital and long term nursing homes as well as in family environments. The direct… More

An Immunoprotectant for Marburg Virus

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$524,876.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Mortality rates associated with Marburg virus (MARV) outbreaks range from 23% to over 90%. MARV is included by the Centers for Disease Control and Prevention as among the Category A agents, or high-priority agents ... that pose a risk to national security. … More

Development of a monoclonal immunoprotectant for ricin

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The National Institutes of Health has deemed the development of therapeutics against potential bioterrorism agents as a national research priority. There is a particular need for antidotes against the toxin ricin (NIAID , 2004); the Centers for Disease Control… More

A Monoclonal Antibody Immunoprotectant for Ebola Virus

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Larry Zeitlin – 443-629-0104
Abstract:
DESCRIPTION (provided by applicant): The National Institutes of Health considers the development of therapeutics against potential bioterrorism agents a national research priority. There is a particular need for immunotherapeutics against Ebola virus (a Category A agent). Because of Ebola's… More

A Monoclonal Cocktail for CDI

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$299,986.00
Agency:
HHS
Principal Investigator:
Andrew Hiatt – 858-625-0335
Abstract:
DESCRIPTION (provided by applicant): Clostridium difficile associated disease (CDI) is an important cause of morbidity in hospital and nursing home patients, and is being increasingly recognized as an important cause of mortality. Estimates put the economic burden of CDI at 1-3 billion dollars in… More

Ricin Toxin Protective Monoclonal Antibodies with Improved Serum Half-Life

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$99,949.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Larry Zeitlin, President – (858) 625-0335
Abstract:
Ricin is a category B toxin due to its ease of acquisition, dissemination, and the high potential for morbidity and mortality after exposure. There are currently no methods of preventing or treating ricin exposure this represents a major unmet need for protection of civilians and warfighters.… More